Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
J Transl Med. 2012 Feb 13;10:29. doi: 10.1186/1479-5876-10-29.
There has been significant progress in the last two decades on the design of chimeric antigen receptors (CAR) for adoptive immunotherapy targeting tumor-associated antigens. Structurally CARs consist of a single chain antibody fragment directed against a tumor-associated antigen fused to an extracellular spacer and transmembrane domain followed by T cell cytoplasmic signaling moieties. Currently several clinical trials are underway using gene modified peripheral blood lymphocytes (PBL) with CARs directed against a variety of tumor associated antigens. Despite the improvements in the design of CARs and expansion of the number of target antigens, there is no universal flow cytometric method available to detect the expression of CARs on the surface of transduced lymphocytes.
Currently anti-fragment antigen binding (Fab) conjugates are most widely used to determine the expression of CARs on gene-modified lymphocytes by flow cytometry. The limitations of these reagents are that many of them are not commercially available, generally they are polyclonal antibodies and often the results are inconsistent. In an effort to develop a simple universal flow cytometric method to detect the expression of CARs, we employed protein L to determine the expression of CARs on transduced lymphocytes. Protein L is an immunoglobulin (Ig)-binding protein that binds to the variable light chains (kappa chain) of Ig without interfering with antigen binding site. Protein L binds to most classes of Ig and also binds to single-chain antibody fragments (scFv) and Fab fragments.
We used CARs derived from both human and murine antibodies to validate this novel protein L based flow cytometric method and the results correlated well with other established methods. Activated human PBLs were transduced with retroviral vectors expressing two human antibody based CARs (anti-EGFRvIII, and anti-VEGFR2), two murine antibody derived CARs (anti-CSPG4, and anti-CD19), and two humanized mouse antibody based CARs (anti-ERBB2, and anti-PSCA). Transduced cells were stained first with biotin labeled protein L followed by phycoerythrin (PE)-conjugated streptavidin (SA) and analyzed by flow cytometry. For comparison, cells were stained in parallel with biotin conjugated goat-anti-mouse Fab or CAR specific fusion proteins. Using protein L, all CAR transduced lymphocytes exhibited specific staining pattern ranging from 40 to 80% of positive cells (compared to untransduced cells) and staining was comparable to the pattern observed with anti-Fab antibodies.
Our data demonstrate the feasibility of employing Protein L as a general reagent for the detection of CAR expression on transduced lymphocytes by flow cytometry.
在过去的二十年中,针对肿瘤相关抗原的嵌合抗原受体(CAR)的设计取得了重大进展,用于过继免疫治疗。从结构上讲,CAR 由针对肿瘤相关抗原的单链抗体片段组成,该片段与细胞外间隔区和跨膜结构域融合,然后是 T 细胞细胞质信号结构域。目前,正在进行几项临床试验,使用针对各种肿瘤相关抗原的 CAR 基因修饰外周血淋巴细胞(PBL)。尽管 CAR 的设计有所改进,并且靶抗原的数量有所增加,但目前尚无通用的流式细胞术方法可用于检测转导淋巴细胞表面的 CAR 表达。
目前,抗片段抗原结合(Fab)缀合物最常用于通过流式细胞术确定基因修饰的淋巴细胞上 CAR 的表达。这些试剂的局限性在于,其中许多试剂不能商业获得,通常它们是多克隆抗体,并且结果常常不一致。为了开发一种简单的通用流式细胞术方法来检测 CAR 的表达,我们使用蛋白 L 来确定转导淋巴细胞上 CAR 的表达。蛋白 L 是一种免疫球蛋白(Ig)结合蛋白,它与 Ig 的可变轻链(kappa 链)结合,而不干扰抗原结合位点。蛋白 L 结合大多数 Ig 类别,也结合单链抗体片段(scFv)和 Fab 片段。
我们使用源自人源和鼠源抗体的 CAR 来验证这种新颖的基于蛋白 L 的流式细胞术方法,结果与其他已建立的方法很好地相关。用逆转录病毒载体转导激活的人 PBL,表达两种人源抗体衍生的 CAR(抗-EGFRvIII 和抗-VEGFR2),两种鼠源抗体衍生的 CAR(抗-CSPG4 和抗-CD19),以及两种人源化鼠源抗体衍生的 CAR(抗-ERBB2 和抗-PSCA)。转导细胞首先用生物素标记的蛋白 L 染色,然后用藻红蛋白(PE)缀合的链霉亲和素(SA)染色,并通过流式细胞术进行分析。为了进行比较,细胞与生物素缀合的山羊抗鼠 Fab 或 CAR 特异性融合蛋白平行染色。使用蛋白 L,所有 CAR 转导的淋巴细胞均表现出特异性染色模式,阳性细胞的比例为 40%至 80%(与未转导的细胞相比),并且与观察到的抗 Fab 抗体的模式相当。
我们的数据表明,使用蛋白 L 作为流式细胞术检测转导淋巴细胞上 CAR 表达的通用试剂是可行的。